Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histological confirmation of invasive, early stage breast cancer~* Prior complete excision of tumor required (wide local excision or mastectomy)~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* Not specified~Sex:~* Female~Menopausal status:~* Pre-, peri-, or post-menopausal~Performance status:~* Not specified~Hematopoietic:~* Adequate bone marrow function~Hepatic:~* Adequate hepatic function~Renal:~* Adequate renal function~Other:~* No prior cancer except for basal cell carcinoma or carcinoma in situ~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Concurrent hormone therapy allowed~Radiotherapy:~* No prior radiotherapy~* Concurrent radiotherapy allowed~Surgery:~* See Disease Characteristics~* No more than 6 weeks since prior surgery to the breast

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).